MockV Solutions Announces Issuance of New Utility Patent for Viral Clearance Platform Technology

Patent provides broad protection for non-infectious viral surrogate technology platform

Rockville, MD – April 28, 2017 – MockV Solutions, Inc. (MockV or the Company), a biotechnology company developing non-infectious viral clearance prediction products that address the unmet needs of process development scientists as they establish biopharmaceutical manufacturing platforms, announced today that the United States Patent and Trademark Office has granted the patent entitled “Methods for Evaluating Viral Clearance from a Biopharmaceutical Solution Employing Mock Virus Particles.” The newly issued patent claims methods of adding non-infectious particles to biopharmaceutical material, processing the material through a purification technique and quantifying the removal of the non-infectious particles by the purification technique. Examples of these broad claims include the use of MockV’s Mock Virus Particles (MVPs) as spiking agents for downstream bioprocessing applications. Similar claims are being pursued in jurisdictions worldwide.

Patent number 9,632,097 was granted on April 25, 2017.

“MockV continues to pursue broad patent coverage for its viral clearance platform technology, first with these method claims and soon by kit composition claims,” stated David A. Cetlin, MS, Chief Executive Officer of MockV Solutions. “Our non-infectious MVPs can be used as accurate and economic surrogates to the live mammalian viruses, which typically serve as spiking agents during viral clearance validation studies. MVPs will enable bioprocess scientists to obtain viral clearance data throughout process development and characterization at a fraction of the current time and costs. Recent published data has demonstrated that our lead MVP, modeled after Minute Virus of Mice, is physicochemically similar to live MVM. MockV is currently evaluating MVM-MVP vs. live MVM removal in side-by-side spiking studies. This recent patent is an important Milestone toward securing a sound patent estate and establishes a platform to pursue or partner this technology as we see fit.”